Kornimate/medical-research-clean huggingface dataset:
comparing the use of dienogest and combined oral contraceptive pills (microgynon) to reduce the risk of recurrence of endometriotic cyst after conservative surgery

Conditions: Endometriosis

Summary: the purpose of the study is to compare the recurrence of endometriotic cyst in patients taking dienogest or microgynon after conservative surgery.


Eligibility criteria:
inclusion criteria: * good general health * older than the age of legal consent (i.e. 18 years old) * sonographic diagnosis of ovarian endometrioma with diameter at least 4cm on 2 separate scans at least 6 weeks apart * no contraindication to use of progesterone or combined oral contraceptive pills * not attempting to conceive either at the time of study entry or for at least 2 years after surgery * willing and able to participate after the study has been explained exclusion criteria: * operative findings not suggestive of endometriotic cyst * contraindications to progestogens or oral contraceptive pills * unwillingness to tolerate menstrual irregularity * planning pregnancy within 2 years of study * cannot understand english, cantonese or putonghua

Keywords: dienogest combined oral contraceptive pills endometriosis
detection of ctcs in stage iii rectal cancer patients undergoing neoadjuvant therapy

Conditions: Rectal Neoplasms; Circulating Tumor Cells

Summary: the purpose of this study is to evaluate the value of dynamic change in detecting ctcs in peripheral blood from stage iii rectal cancer patients undergoing neoadjuvant folfox treatment and chemoradiotherapy,before and after surgery.

circulating tumor cells (ctcs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. enumeration of ctcs in rectal cancer patients could play an important role in diagnosis, predicting the risk for tumor recurrence and effectiveness of neoadjuvant therapy. the investigators choose several timepoints to detect the dynamic change of ctcs,1 day before the 1st ,3rd and 5th(if the patient needs before surgery) neoadjuvant therapy course,1 day before and 7days ,3 month,6 month after surgery. approximately 7.5-ml ethylene diamine tetraacetic acid(edta)-blood was drawn by vein puncture from patients with rectal cancer . briefly, the number of ctcs will be count by the cellsearch system , recorded and analysed by the investigator.

Eligibility criteria:
inclusion criteria: 1. age: \>18 years old. 2. diagnosis of stage iii rectal cancer based on histology. 3. will receive neoadjuvant treatment using folfox or chemoradiotherapy . 4. life expectancy: greater than 3 months. 5. patients have no severe inflammation, such as vasculitis. 6. ability to understand the study protocol and a willingness to sign a written informed consent document exclusion criteria: 1. patients with other primary tumor except rectal cancer. 2. history of coagulation disorders or anemia.

Keywords: circulating tumor cells rectal neoplasms neoadjuvant otherapy
morphine consumption in joint replacement patients, with and without gabapentin treatment, a randomized controlled study

Conditions: Postoperative Pain; Total Hip Replacement

Summary: total hip arthroplasty is amongst the most painful procedures postoperatively, and pain management can be a challenge. different measures have been introduced to manage severe postoperative pain in these patients. previous studies have investigated gabapentin in acute postoperative pain and demonstrated reduced postoperative pain, postoperative morphine consumption, morphine related side effects, and postoperative pain scores. to date, this analgesia adjunct has yet to be investigated for total joint arthroplasty patients.

the study was submitted to health canada and has received the letter of no objection. a randomized, double-blind, placebo-controlled trial will be conducted. the randomization scheme will be prepared and done by the pharmacy department at mcmaster university. ninety patients undergoing primary hip arthroplasty will be recruited from the preoperative clinic. forty-five patients in each population will be allocated to a gabapentin group and the other forty-five patients will be allocated to a placebo group.

Eligibility criteria:
inclusion criteria: * participants aged 19-90 * elective single joint, primary total hip arthroplasty * use of pca with morphine for postoperative pain control has been discussed and agreed upon between patient and anesthetist exclusion criteria: * bilateral total hip arthroplasty * revision hip arthroplasty * underlying diseases of epilepsy, seizure, or chronic pain syndrome * active gastrointestinal bleeding within the last 6 months * history of non-steroidal anti-inflammatory drug (nsaid) induced asthma * known or suspected history of drug or alcohol abuse * participate currently takes gabapentin or pregabalin for any reason * participant currently takes pain medication that is more potency than codeine or oxycodone (morphine, hydromorphone, meperidine, methadone, fentanyl, including any long acting narcotics) * known allergy to study medications: gabapentin, morphine, nsaid, acetaminophen * unable to tolerate morphine * liver impairments * kidney impairment or calculated creatinine clearance by cockcroft-gault formula is \<=60ml/min * pregnancy or breast-feeding * participant currently receives associated worker's compensation benefits (wsib) * participant unable or unwilling to give written or informed consent * unable to use pca

Keywords: hip arthroplasty postoperative pain gabapentin
the cogmed program for youths with adhd

Conditions: ADHD; ADHD - Combined Type

Summary: the primary objective of this study was to examine the effects of the cogmed training program on working memory among youths 7 to 13 years old, while controlling presence and presentation of adhd-related comorbidity. a secondary objective was to examine the generalization of effects to adhd symptoms, non-verbal reasoning, attentional and executive functions, motor impulsivity, reading comprehension, and mathematical reasoning. participants were under pharmacological treatment for adhd combined type and a comorbidity. they were randomized into an experimental group that received the cogmed program and an active control group that received a low-intensity comparison version of the training. they were evaluated at three time points: six weeks prior to intervention onset (t1), immediately prior to onset(t2), and one week following intervention completion (t3).

participants completed the cogmed wm training program at home.each training session lasted from 30 to 45 minutes and was supervised by a parent. for five consecutive weeks, participants had to complete at least five sessions per week.

Eligibility criteria:
inclusion criteria: * (1) be 7 to 13 years old;(2) had to be diagnosed with adhd combined type and present a comorbid learning disability, oppositional defiant disorder or tourette syndrome;and (3) had to be medicated for adhd, exclusion criteria: * youths were excluded from the study if diagnosed with epilepsy, an internalizing disorder (anxiety or mood disorder), an autism-spectrum disorder or mental retardation.

Keywords: adhd combined type cognitive training intervention youths
stratification of stroke rehabilitation: 5-year profiles of functional outcomes

Conditions: Stroke Rehabilitation

Summary: objective: to make use of admission modified functional ambulation category (mfac) as a stratification tool to reveal profiles of functional outcomes of patients with stroke in inpatient rehabilitation. design: this was a retrospective, descriptive study of the demographic, functional outcomes of patients with stroke in an inpatient rehabilitation centre. a total of 2,722 patients completed a stroke rehabilitation program from 2011 to 2015 were recruited.

objective: to make use of admission modified functional ambulation category (mfac) as a stratification tool to reveal profiles of functional outcomes of patients with stroke in inpatient rehabilitation. design: this was a retrospective, descriptive study of the demographic, functional outcomes of patients with stroke in an inpatient rehabilitation centre. a total of 2,722 patients completed a stroke rehabilitation program from 2011 to 2015 were recruited. the patients were divided into seven groups according to their admission modified functional ambulation category (mfac). the between-group difference in length of stay (los), functional outcomes at admission and discharge including modified rivermead mobility index (mrmi) and modified barthel index (mbi) as well as mrmi gain, mrmi efficiency, mbi gain and mbi efficiency were analyzed.

Eligibility criteria:
inclusion criteria: * patients with principal diagnosis of cerebrovascular accident, stroke, or hemiplegia and has received and completed stroke rehabilitation program in a hospital in hong kong between the periods of 1st january 2011 to 31st december 2015. exclusion criteria: * patients with principal diagnosis of cerebrovascular accident, stroke, or hemiplegia and has received but cannot completed stroke rehabilitation program in a hospital in hong kong between the periods of 1st january 2011 to 31st december 2015.
evaluation of different etiologies of obscure ascites

Conditions: Ascites

Summary: ascites refers to fluid that accumulates within the peritoneal cavity. although ascites is most commonly observed in patients with cirrhosis and resulting portal hypertension (approximately 85% of cases), 7% to 10% of patients with ascites develop secondary to a malignancy


Eligibility criteria:
inclusion criteria: * patients with ascites * serum ascites albumin gradient \>1.1. exclusion criteria: * ascitic fluid serum ascites albumin gradient \<1.1. * haemorrgaic ascites; * chylous ascites
radiofrequency-based debridement vs. mechanical debridement for the treatment of articular cartilage lesions

Conditions: Articular Cartilage Disorder of Knee

Summary: the purpose of this study is to evaluate the changes in clinical and imaging outcomes following arthroscopic treatment of chondral lesion(s) by radiofrequency-based debridement or mechanical debridement in subjects 18-50 years of age.

this is a non-inferiority, prospective, single blinded, randomized, single-center study design with enrollment of 82 randomized subjects (to assure 70 subjects complete the study). the sample size of 82 participants was calculated from a power analysis. the study was powered to detect at least a seven point change in koos pain score based on achieving 80% statistical power to detect a non-inferiority margin. study duration will be until the last subject enrolled reaches 52 weeks post-operative. the 82 randomized subjects will be randomized at a 1:1 ratio into the werewolf coblation wand treatment group or mechanical debridement treatment group. subjects will be blinded to their treatment assignment until they complete all study visits. upon withdraw from the study, termination from the study, or new or recurrent symptoms requiring a subsequent arthroscopy, the blinded assignment will be revealed to the subject.

Eligibility criteria:
inclusion criteria: * given written informed consent on the irb approved consent form specific to the study, prior to study participation * 18-50 years old * male or female * suspected chondral damage in the following locations where debridement is indicated: * medial femoral condyle * lateral femoral condyle * trochlea * patella * \< 30% joint space narrowing as seen on x-ray (merchant view, ap and pa rosenberg) * 1 or more chondral lesion(s) as noted on mri exclusion criteria: * previous chondral treatment in the same compartment (prior debridement and lavage performed more than three months prior to baseline are acceptable) * focal chondral defect indicated for concomitant procedures (i.e., microfracture, aci, maci, oats) * concomitant procedures that are not allowed: * lateral retinacular release * excision of osteophytes * subchondroplasty * manipulation under anesthesia * acl reconstruction * quad tendon repair * patellar tendon repair * patellar tendon debridement * multiligament reconstruction * pregnant and/or intending to become pregnant during this study period
a study assessing the safety and efficacy of dextenza® for the treatment of ocular pain and inflammation following surgery for pediatric cataract

Conditions: Cataract

Summary: to assess the safety of dextenza compared to an active control, prednisolone acetate suspension, for the treatment of postoperative pain and inflammation following ocular surgery for pediatric cataract.

randomized, parallel-arm, active control, multi-center study assessing the safety of dextenza for the treatment of ocular pain and inflammation following surgery for pediatric cataract. the subjects will be followed for approximately 2-3 months from screening to the last visit.

Eligibility criteria:
inclusion criteria: * is 0-5 years of age (up to the day before the subject turns 6 years of age). in the event that a subject aged 0-5 years enrolls in the study and then undergoes a second cataract surgery in the contralateral eye during the study period, the subject remains eligible for participation for both eyes, regardless if the second surgery occurs when the subject is \>5 years of age) * has a cataract and is expected to undergo primary cataract surgery with or without implantation of a posterior chamber intraocular lens exclusion criteria: * any intraocular inflammation in the study eye present during the screening slit lamp examination * has ocular hypertension (defined as iop of \>21 mmhg), or glaucoma or is on medications to treat ocular hypertension or glaucoma or has a history of iop spikes in either eye including steroid-related iop increases * evidence of acute external ocular infections (bacterial, viral and/or fungal such as vaccinia, varicella, and other viral diseases of the cornea and conjunctiva), tuberculosis of the eye; corneal dystrophies; active corneal ulcers, intraocular infections, dysthyroid ophthalmopathy, active chalazion, or uncontrolled blepharitis in the study eye

Keywords: dextenza, dexamethasone ophthalmic insert
effects of tiva and inhalation anesthesia on oxidative stress factors during hypotensive anesthesia

Conditions: Oxidative Stress; Anesthesia

Summary: total intravenous anesthesia (tiva) and inhalation anesthesia are two anesthesia methods that can be preferred for the maintenance of anesthesia. sevoflurane and propofol are drugs used frequently in these methods. this study aims to investigate and compare the effects of inhalation anesthesia using sevoflurane and tiva using propofol on oxidative stress in patients undergoing controlled hypotensive anesthesia.

controlled hypotension is defined as keeping systolic blood pressure in the range of 80-90 mmhg or mean arterial pressure in the range of 50-65 mmhg. pharmacological and non-pharmacological methods can be used to achieve controlled hypotension. intravenous anesthetics, inhalation anesthetics, opioids, calcium channel blockers, beta blockers, nitrate derivatives are frequently used drugs for this purpose. general anesthesia maintenance is applied in two ways: total intravenous anesthesia (tiva) and inhalation anesthesia. the pharmacokinetic and pharmacodynamic properties of drugs used in both methods are quite different. products of the body's oxidant antioxidant balance can be measured by biochemical methods and information about this balance can be obtained. thiols are the regions of proteins most susceptible to oxidation, and the conversion of thiols to disulfides and oxyacids is the earliest marker of radical-mediated protein oxidation. total antioxidant status (tas) shows the total effect of all antioxidants in the human body and total oxidant status (tos) shows the total effect of oxidants. in this study, it was aimed to investigate and compare the effects of inhalation anesthesia using sevoflurane and total intravenous anesthesia using propofol on oxidative stress in rhinoplasty cases under controlled hypotension. this assessment was planned using tas (total antioxidant status), tos (total oxidant status), catalase, myeloperoxidase (mpo), total thiol, native thiol and disulfide parameters.

Eligibility criteria:
inclusion criteria: * ages of 18-55 * who will undergo elective rhinoplasty * asa physical status classification system 1 exclusion criteria: * patients with a history of smoking, * patients with a history alcohol use * patients with a history drug use, * body mass index (bmi)\>30 * patients with allergies to drugs to be used * patients who refused to participate in the study termination criteria * whose blood pressure values are out of the targets determined in 3 consecutive measurements

Keywords: total intravenous anesthesia (tiva) inhalation anesthesia thiol-disulphide oxidative stress
fractional laser and ultrasound for striae distensae

Conditions: Stretch Marks

Summary: this was a prospective randomized controlled study comparing the efficacy of micro-focused ultrasound when used in conjunction with 1550-nm erbium-doped fractionated laser versus 1550-nm erbium-doped fractionated laser alone for treatment of striae distensae(stretch marks). each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side and the contralateral side received micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side. the primary outcome measure by two dermatologists blindly compared the two areas of striae distensae on each side from live subjects using a questionnaire and quartile rating scale on the final follow-up visit. this study was a pilot study designed to determine the feasibility of these procedures.

the secondary outcomes were qualitative measurements of the mean striae width in the treatment area before(week0) and after treatment(week10) and subject satisfaction was determined by a satisfaction questionnaire.

Eligibility criteria:
inclusion criteria: * age 18-60 years old male and female subjects with striae distensae on both thighs or both sides of the abdomen. * subjects are in good health. * subjects are willing, have the ability to understand and provide informed consent, and are able to communicate with the investigator. * subjects should be within a 20 lb range of their starting weight during in the study period. exclusion criteria: * pregnant or lactating * subjects who are unable to understand the protocol or give informed consent. * subjects currently under treatment with corticosteroids for any medical problems or subjects who discontinued treatment less than 2 months prior to consent. * subjects who have had medical e.g usage of oral or topical retinoids, laser or surgical treatment for striae distensae within the last year. * subjects who have active skin disease or skin infection in the treatment area. * subjects who are allergic to lidocaine or prilocaine. * subjects who have a history of abnormal scarring.

Keywords: stretch marks striae distensae
nivolumab plus lenvatinib against anaplastic thyroid cancer (navigation)

Conditions: Anaplastic Thyroid Cancer

Summary: this study is an open-label phase 2 study to evaluate the safety and efficacy of nivolumab plus lenvatinib in patients with unresectable anaplastic thyroid cancer.

this study is an open-label phase 2 study to evaluate the safety and efficacy of nivolumab plus lenvatinib in patients with unresectable anaplastic thyroid cancer according to the following steps. step 1 will evaluate the dose-limiting toxicities (dlt) of nivolumab plus lenvatinib in patients with unresectable anaplastic thyroid cancer. step 2 will evaluate the safety and efficacy of nivolumab plus lenvatinib in patients with unresectable anaplastic thyroid cancer.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed as anaplastic thyroid cancer 2. unresectable anaplastic thyroid cancer 3. have measurable lesions defined by the recist version 1.1 4. have adequate organ function 5. cardiac function test within 28 days before enrollment 12-lead electrocardiogram no clinically significant abnormality as shown below: heart disease, severe arrhythmia, etc. 6. patients who are 20 years or older 7. eastern cooperative oncology group (ecog) performance status 0-1 8. ability to swallow oral medications 9. women of childbearing potential 10. life expectancy of more than 90 days 11. have signed written informed consent to participate in this study exclusion criteria: 1. active brain metastases or leptomeningeal metastases 2. diverticulitis or symptomatic ulcerative disease 3. treatment required complication of systemic infectious disease 4. medical history of active, known, or suspected autoimmune disease 5. complication of pulmonary fibrosis or interstitial pneumonitis 6. medical history of clinically significant cardiovascular disease within 180 days of initial dose as new york heart association (nyha) class above 2 leveled congestive heart failure, unstable angina, cardiac infarction or cardiac arrhythmia with paroxysmal or required treatment 7. regardless of usage of antihypertensive drug, systolic blood pressure \<=140 mm hg and diastolic blood pressure \<=90 mm hg 8. have active double cancer 9. currently receiving other interventional clinical study treatment

Keywords: nivolumab lenvatinib anaplastic thyroid cancer
determination and validation of a multi-analyte assay for lung cancer screening

Conditions: Lung Cancer

Summary: this study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.

this is a prospective, case-control, multi-center, observational nonsignificant risk study. the study aims to collect blood and clinical data from subjects undergoing low dose ct (ldct) for lung cancer screening and subjects with confirmed lung cancer.

Eligibility criteria:
inclusion criteria - cases: * current or past smokers, with at least 20 pack-years * subjects with either a high suspicion for lung cancer, with planned surgery to establish a definitive diagnosis within 60 days after date of blood collection or treatment naive lung cancer patients exclusion criteria - cases: * known diagnosis or treatment of any previous cancer, including lung cancer, in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix * current lung cancer is known to be stage iii or iv by pathology. inclusion criteria - screening: - current or past smokers, with at least 20 pack-years, undergoing ldct for lung cancer screening exclusion criteria - screening: * known diagnosis or treatment of any cancer, including lung cancer, in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix * subjects whose purpose of performing ldct is for surveillance of a lung nodule

Keywords: ldct low dose ct lung cancer screening liquid biopsy early detection lung cancer